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Background:  The explosive growth in the rate of X-ray determination of protein
structures is fuelled largely by the expectation that structural information will be
useful for pharmacological and biotechnological applications. For example, there
have been intensive efforts to develop orally administrable antithrombotic drugs
using information about the crystal structures of blood coagulation factors,
including thrombin. Most of the low molecular weight thrombin inhibitors studied
so far are based on arginine and benzamidine. We sought to expand the database
of information on thrombin-inhibitor binding by studying new classes of inhibitors.
Results:  We report the structures of three new inhibitors complexed with
thrombin, two based on 4-aminopyridine and one based on naphthamidine. We
observe several geometry changes in the protein main chain and side chains
which accompany inhibitor binding. The two inhibitors based on 4-aminopyridine
bind in notably different ways: one forms a water-mediated hydrogen bond to 
the active site Ser195, the other induces a rotation of the Ser214–Trp215
peptide plane that is unprecedented in thrombin structures. These binding
modes also differ in their ‘weak’ interactions, including CH–O hydrogen bonds
and interactions between water molecules and aromatic pi-clouds. Induced-fit
structural changes were also seen in the structure of the naphthamidine 
inhibitor complex.
Conclusions:  Protein flexibility and variable water structures are essential
elements in protein–ligand interactions. Ligand design strategies that fail to take
this into account may overlook or underestimate the potential of lead structures.
Further, the significance of ‘weak’ interactions must be considered both in
crystallographic refinement and in analysis of binding mechanisms.
Introduction
The determination of the X-ray crystal structures of throm-
bin [1–4] and other serine proteinases of the coagulation
cascade [5–7] has generated intense interest in the appli-
cation of structure-based drug design to develop new
antithrombotic drugs [8–12]. These structures have illumi-
nated many aspects of thrombin function and of processes
involved in coagulation, including zymogen activation and
cofactor modulation, and have allowed rationalization of
the effects of mutations on activity and an understanding
of the interactions of thrombin with both proteinaceous
and low molecular weight inhibitors. Thrombin, is a classi-
cal ‘trypsin-like’ serine proteinase, and has the typical
structural features of this class of enzymes. But it is also
unique in many respects; the most obvious of these are the
relatively large and partially mobile insertions which mod-
ulate access to the active site region. Other unique features
include its surface charge distribution and exosite binding
sites, a proposed sodium-binding site [13] and the role of
Glu192 in determining substrate specificity [4,14,15].
The search for potentially therapeutic inhibitors of throm-
bin derives from its central role in coagulation [16]. It is
the final enzyme in an amplification cascade that ulti-
mately cleaves fibrinogen to promote stabilization of blood
clots, but it also activates the fibrinolytic system, stimu-
lates platelets, and performs a wide variety of other func-
tions. Several thrombin inhibitors are in clinical trials, and
more are under development. To improve their potency
and/or pharmacological properties, it would be useful to be
able to rapidly determine the binding modes of existing
inhibitors and model modified inhibitors [17–21]. This is
particularly important for new classes of inhibitors, distinct
from the thoroughly studied inhibitors in which benzami-
dine and guanidino groups bind in the S1 specificity
pocket [22–24].
The most successful structure based drug design
methods will be those that can of predict, even approxi-
mately, the binding strengths of modified compounds.
Although great efforts have been made to advance such
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methods, they remain, at best modestly successful; pre-
diction is hindered both by the need to examine an enor-
mous number of possible structures that the protein-
inhibitor complex might theoretically be able to adopt
(sampling) and the problem of estimating the binding
energies of all of these possible structures (scoring). 
The two problems are related: the large number of subtle
interactions which should be considered for greater 
accuracy in energy prediction require, in turn, a finer
sampling of a correspondingly larger number of confor-
mations [25–31].
In this paper we describe binding modes of a new class of
orally available thrombin inhibitors based on 4-aminopyri-
dine (4AP). These inhibitors provide a demonstration of
the difficulties of predicting binding structures: a single
group binds in the specificity pocket S1 in two distinct
ways, either via a bridging water molecule or by inducing a
hitherto unobserved backbone structural change, in which
the peptide plane of Ser214 is rotated 60° across an energy
barrier. The binding interactions are also associated with
changes in the geometries of other interactions,  including
CH–O hydrogen bonds and apparent water-pi cloud inter-
actions. As a further example of induced-fit structural
changes in thrombin, we describe significant main-chain
motions accompanying the binding of naphthamidine
inhibitors and summarize a ‘breathing’ flexibility at the
hydrophobic S2 binding site.
Results and discussion
Binding mode #1: branched inhibitors
The discovery that 4AP can bind in the S1 specificity
pocket of thrombin led to the design of new inhibitors 
by replacing the S1 binding moiety of known thrombin
inhibitors with 4AP. Most notably, the replacement of
benzamidine by 4AP in inhibitors such as NAPAP (Fig. 1)
[22,23] lead to a class of moderately potent thrombin
inhibitors, with inhibition constants typically two orders of
magnitude weaker than the corresponding benzamidine-
based inhibitor [32]. One representative of this class of
inhibitors (BM51.1011) for which we describe the X-ray
crystal structure is depicted in Figure 1; it is closely related
to the classical NAPAP inhibitor [22].
The NAPAP- and TAPAP-like branched inhibitors (Fig. 1)
bind by mimicking natural substrate interactions in the S1,
S2, S3, and ‘aryl’ (or S4) binding sites of thrombin. The S1
site of thrombin is the principal determinant of substrate
specificity, with a clear preference for arginine. The S2 site
prefers small hydrophobic residues, and proline seems pre-
ferred in substrate sequences. In S3, interactions consist of
an antiparallel β sheet hydrogen-bonding pattern with the
main chain of the substrate and do not directly involve side
chains. The side chains may thus be exposed to solvent
implying that polar side chains might be preferred. The
‘aryl’ binding site was so named because of its preference
for large and often aromatic moieties in low molecular
1354 Structure 1996, Vol 4 No 11
Figure 1
Chemical formulas and binding constants (µM
units) of the inhibitors used in this study
BM51.1011, BM14.1248, BM12.1700; and
of inhibitors N-(2-naphthyl-sulphonyl-glycyl)-
DL-p-amidinophenylalanyl-piperidine (NAPAP)
and N-(4-toluene-sulphonyl)-DL-p-
amidinophenylalanyl-piperidine (TAPAP). The
structure of a chloromethylketone analogue,
D-Phe-Pro-Arg which acts as a covalent
inhibitor, is also shown. All of the inhibitors
have a basic group for binding in the
specificity pocket S1 via hydrogen bonds/salt
bridges to Asp189 (shown at the bottom of
the structures). The remaining groups are
designed to fit the S2 and aryl (or S4) binding
sites; NAPAP, TAPAP, BM51.1011, and
BM12.1700 by appropriate branching, and
BM14.1248 as an unbranched inhibitor
utilizing the close proximity of the S2 and aryl
binding sites. The glycine residues of
BM51.1011, and NAPAP and the P1
equivalent backbone in TAPAP bind in an
antiparallel hydrogen bonding pattern to
Gly216; this site (sometimes referred to as
S3) remains unbound and solvent accessible
in BM12.1700 and BM14.1248. In thrombin,
BM12.1700 binds only in the S1 and S2
sites, and the phenoxypyrrolidine is
disordered.
BM51.1011(4 µM) BM14.1248(0.023 µM) BM12.1700(10 µ M)
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weight ligands. For some substrates, it is the P4 residue
that occupies the ‘aryl’ binding site, so it is sometimes
referred to as the S4 site; other studies label it the ‘distal’
site, as it is distant from the catalytic center [24]. But as
some other substrates, such as fibrinogen, bind to this site
with residues other than P4, we will use the name ‘aryl’
binding site here.
The NAPAP and TAPAP inhibitors occupy all of the sub-
strate-binding sites discussed above, but the order of the
S1 and S2 moieties along the chemical ‘backbone’ of the
inhibitors is reversed compared to that in the substrates
(Fig. 1).
The 4AP analog BM51.1011, as expected, occupies the S1,
S2 and aryl binding sites in the same way as NAPAP and
TAPAP do (Fig. 2); detailed interactions differ, however.
The three inhibitors have identical piperidine substituents
in the S2 site, and share the same number of bonds
between the chiral branching point and most peripheral
atom(s) in the S1 site. Differences include the lengths of
the spacers between the S1/S2 and aryl (S4) binding moi-
eties and the flexibilities of the linking chains. As a result,
the binding geometries in all three sites differ signifi-
cantly, even for identical substituents. This illustrates
some of the difficulties inherent in drug design: indepen-
dence and thus additivity of binding energies at different
binding sites cannot generally be assumed, and sub-
stituents suggested by ligand fragment search programs
may be forced to bind with unpredicted and presumably
suboptimal geometries. For example, although NAPAP
and BM51.1011 have identical S2 and S3 binding groups
and have S1 binding groups of identical lengths, they bind
with different geometries in S2 (Fig. 2). This is apparently
because the lengths of the linkers between the sub-
stituents binding in S1 and S2 differ. Unlike the case in
NAPAP, the carbonyl group of BM51.1011 near the S2 site
is bridged to the side chain of Glu192 by a water molecule;
the side chain itself adopts different conformers in the two
structures. The hydrogen bonding patterns of NAPAP,
TAPAP, and BM51.1011 to Gly216 (S3) are qualitatively
similar; the geometry is more ideal for Gly216CO-inhibitor
(sulfonamide) NH bonds than the adjacent Gly216NH-
inhibitor CO bonds. This may be due to the greater acidity
of the sulfonamide proton. The 148 insertion loop, which
may also contribute to inhibitor-binding interactions, was
disordered in the crystal structures.
The binding geometry of 4-aminopyridine in the S1 pocket
is particularly interesting. With the exception of covalent
inhibitors, most thrombin inhibitor structures published 
to date have guanidino, amidino, or primary amino basic
groups in the S1 specificity pocket [6,8]. 4-aminopyridine
provides a sharp contrast to these groups, since its aromatic
bulk is located at the end of the S1 site, in a region where
only polar contacts are normally observed. The polar 4-
amino group is also found in a region where inhibitors typi-
cally bind with saturated hydrocarbons (such as lysine and
arginine) or aromatic groups (benzamidine).
Based on observations of selectivity of 4AP inhibitors for
thrombin and on modelling considerations, a favoured
hypothesis of the binding mode predicted that a salt
bridge is formed between the side chain of Glu192 and
the 4-amino group of the inhibitor. The evidence for this
included the fact that the positive charge of 4AP can be
delocalized between the two nitrogen atoms as a function
of the local electrostatic field, and the fact that Glu192 is
characteristic of thrombin. However, the crystal structure
indicates that the 4-amino group is in an orientation that is
inappropriate for interaction with Glu192; instead, it is
indirectly hydrogen bonded to both Ser214CO and to
Ser195Oγ via an intervening water molecule. This water
molecule has no counterpart in D-Phe-Pro-Arg (PPACK),
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Figure 2
BM51.1011 (thick-stick model) with bridging
water molecule and its superposition with
NAPAP (blue ball-and-stick model) and
TAPAP (green stick model). While the general
binding arrangements of NAPAP, TAPAP and
BM51.1011 agree, detailed interactions vary,
and the solvent structure involved in binding is
different. BM51.1011 binds via a bridging
water molecule (red sphere with distances)
connecting Ser214CO, Ser195Oγ, the
4-amino group of BM51.1011, and a second
water molecule.
NAPAP, or TAPAP–thrombin complexes, in which the
inhibitor occupies this volume.
The pyridine nitrogen forms a salt bridge to Asp189, at
approximately equal distances to each of the carboxylate
oxygen atoms. The orientation of the ring indicates a
hydrogen position approximately co-linear with the nitro-
gen atom and one of the oxygen atoms (schematically
depicted in Figure 3), although the resolution of the struc-
ture does not determine this unambiguously. Any such
asymmetry is likely to influence the charge distribution in
the carboxylate group of Asp189 and to introduce asym-
metry, especially considering the observation that pK
shifts are associated with inhibitor binding [33]; very high
resolution structures are need to address this issue. The
orientation of the pyridine ring observed here also posi-
tions one of the 4AP C–H bonds in a geometry appropriate
for a CH–O hydrogen bond to a water molecule found
conserved in the S1 pocket (see discussion of solvent
interactions below).
Binding mode #2: unbranched inhibitors
The second class of 4AP inhibitors, represented by
BM14.1248 (Fig. 1) is more closely related to the original
structure found during screening of Boehringer Mannheim
in-house substance libraries. The arrangement of S1, S2,
and S4 binding groups is unbranched, utilizing the close
proximity of the S2 and S4 binding sites as in D-Phe-Pro-
Arg inhibitors [1] and reflecting thrombin’s preference for
proline in the P2 position. The order of magnitude of the
Ki value for BM14.1248 (23 nM) is typical for this series of
‘unbranched’ inhibitors, as is the two order of magnitude
improvement over the ‘branched’, NAPAP/TAPAP analog
inhibitors represented by BM51.1011. Several crystal struc-
tures were determined for inhibitors of this class.
All 4AP inhibitors of this class determined thus far show 
a  mode of binding distinct from that of the branched
inhibitors. The bridging water of the NAPAP-analog 4AP
inhibitors (BM51.1011) is not present in these structures;
instead, the 4-amino group is hydrogen bonded directly to
Ser214CO after rotation of the peptide plane defined by
Ser214 and Trp215, involving angles ψ and φ, respectively.
This peptide plane rotation has a number of consequences,
depicted in Figure 3. Ser214, sometimes called the fourth
member of the catalytic tetrad of serine proteinases because
of its conserved interactions with Asp102 [34], is usually
found with its peptide carbonyl group in an appropriate
geometry for CH–O hydrogen bonding with the catalytic
His57 [35]. In addition, the corresponding peptide amino
group of Trp215 forms a hydrogen bond to the underlying
Phe227CO, although its geometry might indicate a rather
weak interaction. The rotation of the peptide plane breaks
each of these interactions (Figs 3,4). This main-chain con-
formation is conserved in other thrombin structures,
perhaps suggesting that the change in main chain confor-
mation observed here is costly in terms of binding
enthalpies. The cost might have contributions both from
intrinsic, intra-residue interactions (such as depicted in a
Ramachandran plot) and from protein packing and folding
1356 Structure 1996, Vol 4 No 11
Figure 3
Schematic summary of the binding
interactions of the two binding modes.
(a) Binding mode of the branched inhibitor
BM51.1011. (b) Binding mode of the
unbranched inhibitor BM14.248. The
specificity pocket S1 of arginine/lysine
specific serine proteinases is formed most
prominently by Asp189 at its base, but a
hydrophobic sleeve and an extended
hydrogen bonding network are also
characteristic. The hydrogen bonding
network, shown with dashed lines (red for
‘weak’ interactions) extends to the active site
triad (or tetrad if Ser214 is included [34])
and typically includes a CH–O interaction
between His57Cε1 and Ser214CO [35].
Two water molecules usually present
[2,37,43] are W1 between Asp189 and
Tyr228, and W2 between Tyr228,
Trp215CO and Phe227CO. The two binding
modes of 4AP reported here affect all of
these interactions. The binding of 4AP in the
‘linear’ inhibitors induces a rotation of the
peptide plane of Ser214–Trp215. Water in
the active site is clear in the electron density
and has a close packing interaction with the
4AP ring in the plane of the ring. The rotation
of the peptide plane disrupts a hydrogen
bond normally (weakly) formed between
Trp215NH and 227PheCO.
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considerations. A Ramachandran plot of this transition
shows a rough equivalence of the local geometric energies
of Ser214 and Trp215 before and after the transition, with 
a somewhat more strained configuration for Ser214 after
crossing an energy barrier (Fig. 5). The possible optimiza-
tion of hydrogen-bonding interactions between the 4-amino
group and Ser214CO may compensate for the energy costs,
as well as binding energies at the more distant S2 and 
aryl binding sites. Because 4AP alone does not measurably
inhibit thrombin (WvdS, unpublished data), a significant
contribution to the energy required for the conformational
change must come from the other binding sites.
This binding mode also involves a partial rotation of the
4AP group compared to BM51.1011 such that the proton of
the pyridine NH is co-linear with one of other carboxylate
oxygens of Asp189. (At this level of detail, however, the
structure may be influenced by refinement constraints.)
Water molecule W2 is more ideally hydrogen bonded to
Phe227CO, and is packed closely against the 4AP ring
without the apparent colinear CH–O binding geometry 
of BM51.1011. On the one hand, the partial rotation may
force the water toward Phe227CO, while, on the other
hand, the loss of the hydrogen bond between Phe227CO
and Trp215NH may free the carbonyl group to adopt a
more ideal binding geometry with the water molecule. In
general, the hydrogen-bonding network in and about the
binding site is apparently reduced.
Outside the S1 binding pocket, there are no specific polar
interactions with thrombin. The usual S3 binding interac-
tions of hydrogen bonding with Gly216 are not present; the
sulfonamide nitrogen might have been a candidate for such
an interaction but it remains accessible to solvent and
appears not to form a hydrogen bond directly to the protein.
Gly216N is within 3.5 Å of the ether oxygen of BM14.1248,
rather far for designation as a weak ether hydrogen bond.
Gly216O remains accessible to solvent with no evidence of
ordered water.
The phenyl group in the aryl binding site is found in a per-
pendicular stacking arrangement with Trp215 (closest
approach 3.47Å). Other close packing contacts (under 3.5 Å)
are with Ile174 and Cα of Asn98; Tyr60A (single letters
denote insertion position relative to chymotrypsinogen) and
Leu99, which mark the ‘border’ between the S2 and aryl
binding sites, are within 4Å. As in the BM51.1011 structure,
the 148 loop is disordered in the structure.
‘Breathing’ in the S2 binding pocket
The S2 binding pocket is lined by hydrophobic Leu99 and
Trp215Cα,Cβ and by aromatic residues Tyr60A, Trp60D
and His57; Tyr60A and Trp60D form an ideal perpendic-
ular aromatic stacking arrangement. The aromatic groups
of the unbranched 4AP inhibitors have at least the poten-
tial for aromatic stacking interactions in S2. However, the
methyl group of the BM14.1248 dominates the interaction
with Tyr60A nearly symmetrically over the plane of the
ring with distances of 3.6–3.7Å to each aromatic carbon
atom. The closest interactions between Trp60D and
BM14.1248 are between the edge of the tryptophan (CZ2,
CH2) and the aromatic-ring carbons (3.4A). These relative
orientations do not form the ideal geometries commonly
described for pi-stacking interactions.
Substitution at the meta-position of the S2-bound phenyl
ring was important in the strategy for optimizing the
binding strengths of this series of inhibitors. Groups ranging
in size from hydrogen to methoxy (Kis of 79 nM and170 nM
respectively) were substituted; optimal binding (Ki of
23nM) was found for the methyl group of BM14.1248.
Superposition of crystal structures of several of these
inhibitors show variations of the 60A–D (YPPW) insertion
loop which can accommodate the changes (Fig. 6), to a
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Figure 4
Detail of 4AP binding mode of BM14.1248.
The 2Fo–Fc electron density map of the final
model is superimposed with the Fo–Fc
electron density map of the the structure prior
to the addition of water molecules. Polar
hydrogen atom positions on the 4AP moiety
are shown for clarity. The main characterizing
features of this binding mode are evident: the
pyridine nitrogen asymmetrically forms a
hydrogen bond with one oxygen of Asp189, a
water molecule is closely packed to the ring in
the plane of the ring, and the peptide plane of
Ser214–Trp215 is rotated to form a hydrogen
bond between Ser214CO and the 4-amino
group of 4AP.
perhaps surprising degree. The flexibility of the loop is par-
ticularly important considering its role in many substrate
interactions [36].
The variations in the loop positions are correlated also with
changes in the positions of Trp96, which packs tightly
against the tripeptide 60A–C (YPP). Although the varia-
tions in the position of Tyr60A are relatively uniformly 
distributed, those of Trp60D and the main chain of the
insertion are clustered. This clustering is apparently related
to the packing interactions in the crystal, in particular those
involving Asp60E. Using the conditions described below
bovine thrombin has been crystallized into several space
groups and cell dimensions; all have essentially the same
packing but differ in the extent of symmetry and in the
interactions involving Asp60E. The uniform distribution of
Tyr60A variations may indicate that a relatively uniform
‘breathing’ of the S2 site is possible in solution. However,
crystallization into one of two crystal forms preferentially
induces one of two conformations of the main chain.
Naphthamidine binding
The naphthamidine base of BM12.1700 (Fig. 1) corre-
sponds to benzamidine in the NAPAP-like inhibitors 
and appears in a class of factor X specific inhibitors [14].
Depending on their composition, and in particular on the
occurrence of a hydrophobic group such as the ethyl ester
of BM12.1700, they may also inhibit thrombin. The crystal
structure of BM12.1700 bound to thrombin shows a sym-
metric, twin–twin binding mode, similar to the benzami-
dine binding mode in NAPAP [23], whereby two parallel
hydrogen bonds link Asp189 with the amidino group, each
linking one carboxylate oxygen atom of Asp189 with one
amidino nitrogen hydrogen. One amidino nitrogen is
further hydrogen bonded to Gly219CO, while the other 
is hydrogen bonded to a water molecule labelled W2 
in Figure 3 (This water corresponds to waters numbered
W50 in [37] and 305 in [2]). Although this is the ‘sym-
metric’ binding mode, asymmetry arises in the hydrogen
bonding to Asp189, where the nitrogen atom H-bonded to
Gly219CO shares a 2.8Å hydrogen bond with Asp189Oδ1,
while the water bound nitrogen makes a 3.2Å hydrogen
bond to Asp189Oδ2.
In stark contrast to the NAPAP structures however, 
and indeed to all thrombin inhibitor structures reported so
far, BM12.1700 induces a main-chain transformation at
position Glu192 in which residues 191–193 are translated
by 1.5–2.0Å away from their normal position (Fig. 7). This
motion, constricting the S1 pocket, is accomplished
without any single hinge, but by cumulative alterations of
main-chain angles of residues 189–194. Flexibility of this
segment has been described in connection with D-Phe-Pro-
Arg binding in the S1 pocket [4], where the arginine-bound
S1 pocket is slightly compressed compared with hirugen-
bound thrombin, which has a water-filled S1 pocket.
The energy required to alter the thrombin structure 
must come either directly from the binding of naphthami-
dine or indirectly from the optimization of more distant
interactions, such as those at the S2 site. Since naphthami-
dine binding to factor Xa shows a similar induced fit
mechanism [38] even though it has completely different
interactions at S2, the structural change seems likely to
result directly from binding the naphthamidine moiety.
(Interestingly, naphthamidine-bound trypsin also has this
geometry [39]; however, for trypsin this is normal.)
Solvent interactions, weak interactions, flexibility and drug
design
The immediate aim of structure determination of an
enzyme bound to a potentially therapeutic inhibitor is
usually the design of improvements to that inhibitor. By
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Figure 5
Ramachandran plot showing the transitions of the peptide rotation
accompanying 4AP binding. Triangles indicate Φ-Ψ angles of Ser214
and circles indicate Φ-Ψ angles of Trp215. Colors indicate the
following: blue denotes Φ-Ψ angles for Ser214 of NAPAP, TAPAP,
PPACK and BM51.1011 complexes; purple denotes Φ-Ψ angles for
Ser214 of 4AP inhibitor bound thrombin complexes; pink denotes Φ-Ψ
angles for Trp215 of NAPAP, TAPAP, PPACK and BM51.1011
complexes; and black denotes Φ-Ψ angles for Trp215 of 4AP bound
inhibitor complexes. Lines connect the points for BM51.1011 and
BM14.1248. The Ψ angle of Ser214 and the Φ angle of Trp215 are
simultaneously altered, locally rotating the peptide plane without
significant alteration elsewhere along the main chain. Contours
showing the frequency distribution [50] of Φ-Ψ angles in the
Brookhaven Data Base [51] show that the rotation of the peptide plane
involves a transition across an energy barrier for Ser214.
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identifying interactions involved in binding, providing
some estimate of their contributions to binding, and analyz-
ing possible additional or alternative interactions, potency
may be improved. It may be equally important to establish
positions on an inhibitor where modifications are unlikely
to affect binding but may improve pharmacological or toxi-
cological properties. Any of these strategies would benefit
substantially from improved methods for the prediction of
the effects of alterations on binding.
The inhibitor structures described here highlight the diffi-
culties involved in the theoretical prediction of binding
energies. Both the protein and ligand are flexible, and the
protein flexibility shown here could have been only par-
tially anticipated from the many thrombin structures pre-
viously determined. Binding involves hydrogen bonding
through water molecules (or ions interpreted as water mol-
ecules) whose positions also change.
Large scale flexibility in thrombin was first observed in
the comparison between the structures of D-Phe-Pro-Arg-
bound thrombin [1] and hirudin-bound thrombin [40]; the
148 insertion loop formed a completely different fold.
Interactions with co-factors and hirudin-based inhibitors
further suggested allosteric control of substrate selectivity
and catalysis. As mentioned above, the loop surrounding
Glu192 had been observed to shift slightly as a conse-
quence of arginine binding [4]. However, the magnitudes
of the motions described here and in particular the rota-
tion of the peptide plane seem unpredictable. The latter
also represents a change in character of the protein surface,
as a relatively hydrophobic peptide plane is replaced by
the hydrophilic carbonyl group.
A variety of subtle water interactions have been well docu-
mented [34,41,42]. The water molecule corresponding to
W2 of Figure 3, has been identified in trypsin by neutron
Research Article Thrombin-ligand interactions Engh et al. 1359
Figure 6
Variations in the position of the insertion loop
60A–60D (YPPW), unique to thrombin, lead
to a ‘breathing’ in the S2 binding pocket
which can accommodate S2 groups of
different sizes. The variations can be seen to
form two clusters along the backbone and
including the side chains of Trp60D and
Asp60E. This clustering is related to the
crystal symmetry, which in turn suggests that
the identity of the inhibitor at the S2 site may
influence the crystallization. Atoms shown
here are in standard colors.
Figure 7
Thrombin structure as bound to BM12.1700
(yellow; atoms in standard colors). Thrombin
structures as bound to NAPAP (blue), TAPAP
(green), and BM12.1248 (red) are super-
imposed for comparison. The naphthamidine
of BM12.1700 binds analogously to the
benzamidine of NAPAP, with an identical
hydrogen bond arrangement, but the orien-
tations of the rings differ, and the naphthami-
dine group induces a constriction of the S1
pocket as the main chain of Glu192 moves by
up to 2 Å. 
diffraction [43] as being in a two-water cluster in a
‘hydrophobic’ pocket probably stabilized by the pi-cloud of
Tyr228. Compared to conserved water W1 (Fig. 3), this
water is generally more likely to be disordered in crystal
structures, making an analysis of its position(s) and occu-
pancy more difficult. A water W2 is disordered in the struc-
ture of thrombin with BM12.1700,  but in the structure with
BM14.1248 is highly ordered, but in close contact with the
4AP ring. This contact may or may not be repulsive. It is
close enough that the standard protein refinement parame-
terization of XPLOR moves the water from a central posi-
tion in the initial unbiased difference density (Fig. 5).
Finally, the bridging water in the binding mode of 4AP
inhibitor BM51.1011 may represent a water position occu-
pied during the approach of the 4AP inhibitors of the
second class [34].
Hydrogen bonds of the CH–O type are often seen in pro-
teins. This interaction is generally described as a princi-
pally electrostatic one [35,44–46], and has been analysed
explicitly in connection with water molecules [46]. We
observe an apparent CH–O bond in the first 4AP binding
mode, and a conserved CH–O hydrogen bond [35] that is
broken by the rotation of peptide plane of Ser214–Trp215.
Estimates of the energies of these interactions range from
0.3kcal mol–1 to values up to 10 times as high for polarized
C–H bonds [44,45]. The observation that an inhibitor is
both directly involved in such contacts, and indirectly
involved in altering the hydrogen- bonding network in the
protein, including both NH–O hydrogen bond and CH–O
interactions, highlights the complexities of protein-ligand
interactions and the difficulties involved in detailed theo-
retical approaches to the problem.
Although we emphasize here that the subtleties involved
in protein–ligand interactions prevent, at least for the
present, a quantitative analysis of binding properties and
even more so quantitative predictions of binding proper-
ties of altered ligands and proteins, crystal structure-based
drug design does work at an important qualitative and
intuitive level. Simple visualization or measurement of
parameters such as volume, hydrophobic surface area and
so on contributes both to a fundamental understanding of
protein–ligand interactions, and to improved predictions.
For example, although the S2 site described here is
subject to fluctuations, the overall volume and hydropho-
bic surface are is approximately conserved, and optimal
ligands will most probably be ones that bind with the con-
served and therefore energetically favored geometry. The
modifications at the S1 site described here for thrombin
are exceptional in that they change both the polarity of the
binding surface (by the rotation of the peptide plane) and
the volume of the S1 binding pocket (the movement of
the main chain of Glu192 upon naphthamidine binding).
The central importance of proteins such as thrombin justi-
fies the effort to determine many structures under many
conditions. The accumulation thereby of unpredictable
observations should significantly enhance molecular mod-
eling capabilities for individual proteins.
Biological implications
Our study of the interactions between low molecular
weight inhibitors and thrombin, a clinically important
target, emphasizes the difficulties inherent in the use of a
limited set of protein–ligand structures to predict inhibitor
binding. We find that inhibitors can cause conformational
changes at several sites of interaction generating an
induced fit, identical chemical substituents can show dif-
ferent binding geometries, ‘weak’ interactions are com-
monplace and water molecules readily adapt to variations
in protein–ligand interactions. Detailed structural inter-
pretation of protein–ligand interactions requires consider-
ation of a complex set of many subtle interactions,
especially where modifications of interacting groups are
to be analyzed. This is true whether the aim is to analyze
the substrate or cofactor specificities or to allow the
design of proteins of altered characteristics. Although a
general solution for this problem is currently outside our
reach, for important and extensively–studied proteins like
thrombin it may be possible to improve the success of
structure-based design of ligands by detailed structural
characterization of the subtle interactions characteristic
of the protein in question, including any complicating fea-
tures such as allostery or cofactor interactions.
Materials and methods
Human thrombin—BM51.1011 crystals were produced from a 10mg–1ml
solution of human thrombin [2], prepared in a 25mM citrate/1mM EDTA
buffer at pH6.9. The inhibitor (2.5µl of a 10mM  dimethylsulfoxide
(DMSO) solution of BM51.1011) was co-crystallized with 22.5 µl of the
thrombin solution over a reservoir of a pH 8.8 buffer consisting of 0.2M
lithium sulfate, 0.1M TRIS, and 30% PEG 4000 as precipitant; the 
crystallization drop initially contained equal volumes of the protein and
inhibitor and reservoir solutions. After several days, rod- like crystals dif-
fracting to 2.8Å were harvested. Data were collected on a Siemens
X1000 wire array diffractometer using FRAMBO/SADIE  collection soft-
ware. Data evaluation done with SAINT [47] established a P622 cell
(a=81.684, c=186.40) with the systematic extinctions of P6(1)22 or
P6(5)22; the R factor for merging data was 7.9%.
Co-crystals of bovine thrombin [23] were produced by vapour diffusion
techniques using in general screening reservoir solutions of 1.6, 1.7
and 1.8 M ammonium sulfate (AS) buffered at pH7 or 8 with 0.1M
TRIS; a protein solution consisting of 10mg–1ml bovine thrombin was
mixed with reservoir at a 1:1 ratio in ChrysChem crystallization plates.
The crystal of bovine thrombin with BM14.1248 (P42212, a = b= 87.5,
c = 103.2, diffracting to 2.5Å; R merge = 9.9 %) was taken from a 1.7M
AS and pH7 crystallization trial, and the co-crystal with BM12.1700
(a = b = 87.0, c = 103.2, diffracting to 2.8Å; R merge = 6.0 %) was
taken from 1.8M AS and pH 7.
For the solution of BM51.1011 in the new hexagonal crystal form, 
rotation and translation searches were performed with the program
X-PLOR [48]. Structure determination and refinement began with initial
models from either human thrombin–PPACK thrombin coordinates [1]
or bovine thrombin–NAPAP coordinates (PDB code: 1ETS); cyclic
procedures of model building with O [49] and refinement with X-PLOR
including restrained individual B factor refinement were stopped 
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with final R factors of 20.8 % (BM51.1011, 38 solvent molecules),
21.8 % (BM12.1248, 47 solvent molecules) and 22.6 % (BM12.1700,
no solvent).
Accession Numbers
The coordinates for the three complex structures have been deposited
with the Brookhaven Databank: human thrombin–BM51.1011 complex,
PDB ID code 1UVS; bovine thrombin–BM14.1248 complex, PDB 
ID code 1UVT; and bovine thrombin–BM12.1700 complex, PDB ID
code 1UVU.
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